Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, First-in-Human, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study of the Safety and Efficacy of Allogeneic Mesenchymal Stem Cells in Cancer Survivors With Anthracycline-Induced Cardiomyopathy

NCT02509156 is registered in ClinicalTrials.gov with The University of Texas Health Science Center, Houston as lead sponsor.

NCT NCT02509156
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02509156 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, First-in-Human, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study of the Safety and Efficacy of Allogeneic Mesenchymal Stem Cells in Cancer Survivors With Anthracycline-Induced Cardiomyopathy
Lead sponsor
The University of Texas Health Science Center, Houston
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2016
Completion date
April 20, 2020
Enrollment
46 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

cardiomyopathy due to anthracyclines